Overview of Metoclopramida Labesfal
| Property | Description |
|---|---|
| Active ingredient | Metoclopramide |
| Forms | Tablet, Oral solution, Injectable solution |
| Pharmacological class | Prokinetic Agent, Antiemetic Agent |
| Origin | Synthetic (Substituted Benzamide Derivative) |
| Route of administration | Oral, Intravenous (IV), Intramuscular (IM) |
Metoclopramida Labesfal is a prescription-only medicinal product containing the single active substance Metoclopramide (INN), which is precisely defined as a synthetic substituted benzamide derivative. The product functions as a dual-action agent, primarily classified as a Prokinetic Agent and an Antiemetic Agent, making it instrumental in regulating the movement of the upper digestive system and suppressing feelings of nausea.
What Type of Medicine is Metoclopramida Labesfal?
Metoclopramide is a pharmacological compound primarily categorized by its effects on specific chemical messengers in the body, most notably by acting as a Dopamine D2 Receptor Antagonist. This molecular action is responsible for both of its high-level classifications. As a Prokinetic Agent, the substance enhances the natural, forward-moving contractions of the muscles in the stomach and small intestine, thereby speeding up the transit of contents, an effect clinically recognized for its efficacy in managing conditions characterized by sluggish gastric movement.
Its secondary, yet critical, role as an Antiemetic Agent stems from its ability to block the dopamine-mediated signals in the brain’s chemoreceptor trigger zone (CTZ), which prevents the initiation of the vomiting reflex. Metoclopramide-containing products are recognized for their gastroprokinetic and antiemetic properties, confirming the dual purpose of the substance.
Available Forms and General Purpose
The medication is supplied for patient use in multiple dosage forms, including traditional tablets for oral intake, an oral solution that allows for dosage adjustment, and an injectable solution for parenteral administration via the intravenous (IV) or intramuscular (IM) route of administration. The drug's overall purpose is to restore coordinated movement in the upper digestive system. By accelerating stomach emptying and simultaneously blocking the brain’s nausea signals, the substance generally helps to relieve feelings of persistent nausea, prevent vomiting, and alleviate symptoms associated with sluggish stomach emptying.
Regulatory References

